Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This volume contains the main proceedings of the fourth international conference on "Cancer Prevention 2006," which was held during February 16–18, 2006, in St. Gallen, Switzerland. Written by international experts in the field, the book comprises a comprehensive update on the most recent developments in the upsurging fields of molecular biology and cancer genetics and their interactions with clinical epidemiology and cancer prevention at various levels: genetic/biologic predisposition and definition of high-risk groups; preclinical models and tumor prevention; prospects of surrogate endpoints and biomarkers; progress in imaging and detection of neoplastic precursor lesions; problems with Cox-2 inhibitors in tumor chemoprevention; primary and secondary prevention of gynecological, breast, gastrointestinal and genitourinary cancers. In addition, the future prospects of cancer chemoprevention are discussed.

Cancer --- Oncology --- Prevention --- Tumors

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

More than 180 participants and experts from 31 countries met for the fifth time in 10 years in St. Gallen, Switzerland for a 3-day conference to discuss important current issues of clinical cancer prevention. The meeting was again organized and co-sponsored by St. Gallen Oncology Conferences (SONK). While SONK has been extremely successful in organizing large international c- gresses on “Primary Therapy of Early Breast Cancer” as well as “Supportive Care in Cancer” for more than 20 years, the idea of promoting interdisciplinary, clinically oriented meetings on cancer prevention is a more recent and not yet generally accepted and w- comed concept in modern oncology. Since today’s medical expenses are soaring and me- cal research budgets are stagnating or even being cut, neither politicians nor industry is willing to risk an additional unpredictable channel of expenses, such as that demanded by clinical cancer prevention efforts! In Switzerland—and we fear in many other parts of the globe—some 97%–98% or even a greater percentage of health budgets is spent for curative and palliative/rehabilitative m- icine. Since a meager 2%–3% of national health budgets is for preventive medicine, even less than that proportion is specifically allocated for cancer prevention. When the money for “curing and caring” for the diseased populace runs short, there is likely not much left for partly controversial disease prevention in the (still) healthy part of the population.

Cancer -- Genetic aspects -- Congresses. --- Cancer -- Genetic aspects. --- Cancer -- Prevention -- Congresses. --- Cancer -- Prevention. --- Chemoprevention -- Congresses. --- Neoplasms -- genetics -- Congresses. --- Cancer --- Biology --- Diseases --- Drug Therapy --- Publication Formats --- Therapeutics --- Biological Science Disciplines --- Publication Characteristics --- Natural Science Disciplines --- Analytical, Diagnostic and Therapeutic Techniques and Equipment --- Disciplines and Occupations --- Genetics --- Congresses --- Chemoprevention --- Neoplasms --- Medicine --- Health & Biological Sciences --- Oncology --- Prevention --- Genetic aspects --- Medicine. --- Cancer research. --- Oncology. --- Medicine & Public Health. --- Cancer Research. --- Tumors --- Cancer research --- Clinical sciences --- Medical profession --- Human biology --- Life sciences --- Medical sciences --- Pathology --- Physicians